Bayer has entered a non-binding Memorandum of Understanding with Chromedix Pharmaceuticals and the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC), witnessed by the Delegation of the European Union to Nigeria and ECOWAS. The parties will explore phased collaboration on distribution, capacity building, and potential technology transfer—starting with short-acting hormonal contraceptives—to strengthen local supply resilience and broaden access to essential medicines. Discussions are exploratory and subject to due diligence, regulatory approvals, and definitive agreements. Read more

_{This MoU is non-binding and exploratory. Any future activities are subject to due diligence, regulatory approvals, and mutually agreed definitive contracts.}